HF-IMP · Heart Failure Intelligent Management Platform

Select clinical phase

Choose the patient's current care setting. The platform routes directly to the appropriate workflow.

🚨

Emergency Department Phase 1

Acute dyspnoea, suspected decompensated HF, or haemodynamic instability. Rapid diagnosis and immediate treatment guidance.

Acute HFPhenotypingRisk stratificationDisposition

›

🏥

Inpatient Ward / HDU Phase 2

Patient admitted for heart failure. Daily decongestion tracking, diuretic optimisation, GDMT initiation, and discharge planning.

DecongestionDaily roundGDMT initiationDischarge

›

📋

Outpatient Cardiology Clinic Phase 3

Stable patient at HF clinic. GDMT optimisation with local formulary awareness, uptitration planning, and rehospitalisation risk assessment.

GDMT optimizerLocal formulary4 pillarsBPJS aware

›

Biomarkers & Vitals

MAP calculates automatically as you type.

Biomarkers

BNP

pg/mL

NT-proBNP available?

No

Blood pressure & heart rate

SBP

mmHg

DBP

mmHg

Heart rate

x/min

MAP (auto-calculated)— mmHg

Respiratory

SpO₂

%

RR

br/min

References & Evidence BaseExpand ▽

1McDonagh TA et al. 2023 Focused Update ESC HF Guidelines. Eur Heart J. 2023.

2Heidenreich PA et al. 2022 AHA/ACC/HFSA HF Guideline. JACC. 2022;79(17):e263–e421.

3Maisel AS et al. Rapid BNP in ED diagnosis of HF. NEJM. 2002;347(3):161–167.

4Nohria A et al. Hemodynamic profiles in HF. JACC. 2003;41(10):1797–1804.

Daily Round Entry

Enter today's data. eGFR auto-calculates via CKD-EPI 2021.

Patient demographics (for eGFR)

Age

years

Sex

Male

Female

Weight monitoring

Admission weight

kg

Today's weight

kg

Weight change from admission— kg

Fluid balance & diuretics

Urine output (24h)

mL

Furosemide dose

mg IV

Renal function & electrolytes

Creatinine

mg/dL

Baseline Cr

mg/dL

K⁺

mEq

eGFR · CKD-EPI 2021

Enter Cr + age

—

Creatinine rise vs baseline—

Vitals & hospital day

SBP

mmHg

HR

bpm

Hospital day

day

References & Evidence BaseExpand ▽

1Felker GM et al. Diuretic strategies in AHF (DOSE trial). NEJM. 2011;364(9):797–805.

2Mebazaa A et al. STRONG-HF. Lancet. 2022;400(10367):1938–1952.

3Inker LA et al. CKD-EPI 2021. NEJM. 2021;385(19):1737–1749.

4McDonagh TA et al. 2023 ESC HF Guidelines. Eur Heart J. 2023.

Patient Profile

Enter patient details. eGFR auto-calculates via CKD-EPI 2021.

Demographics

Age

years

Sex

Male

Female

NYHA Class

I

II

III

IV

Ejection fraction

%

Vitals & laboratory

SBP

mmHg

HR

bpm

Creatinine

mg/dL

K⁺

mEq

BNP

pg/mL

eGFR · CKD-EPI 2021

Enter Cr + age

—

References & Evidence BaseExpand ▽

1Heidenreich PA et al. 2022 AHA/ACC/HFSA HF Guideline. JACC. 2022.

2McMurray JJV et al. PARADIGM-HF. NEJM. 2014;371:993–1004.

3CIBIS-II Investigators. Bisoprolol in HF. Lancet. 1999;353:9–13.

4Packer M et al. COPERNICUS (Carvedilol). NEJM. 2001;344:1651–1658.

5Pfeffer MA et al. CHARM (Candesartan). Lancet. 2003;362:759–766.

6McMurray JJV et al. DAPA-HF. NEJM. 2019;381:1995–2008.

7Packer M et al. EMPEROR-Reduced. NEJM. 2020;383:1413–1424.

8Mebazaa A et al. STRONG-HF. Lancet. 2022;400:1938–1952.

9Inker LA et al. CKD-EPI 2021. NEJM. 2021;385:1737–1749.